Compare Goldman Sachs Group Inc (GS) vs TG Therapeutics Inc (TGTX) Price & Performance

Goldman Sachs (GS) trades at $1,034.41, showing minimal daily movement with a neutral technical stance. The company demonstrates strong fundamental performance with three consecutive quarterly earnings beats and robust profitability metrics including 31.68% net income margin and 18.34% ROE. Recent developments include securing lead roles in high-profile IPOs including Anthropic and SpaceX, positioning the firm for investment banking growth amid expectations of near-record M&A activity in 2026.

The outlook remains positive with analyst consensus targeting $1,160 representing 12% upside potential. Key opportunities include the upcoming IPO wave and strong investment banking pipeline, while risks involve volatile cash flow patterns and market sensitivity to economic conditions. The stock presents a compelling value proposition with a reasonable P/E of 15.97 amid strong earnings momentum.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.